Sofie Rutsaert
Overview
Explore the profile of Sofie Rutsaert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
447
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Adams P, Fievez V, Schober R, Amand M, Iserentant G, Rutsaert S, et al.
iScience
. 2020 Dec;
24(1):101881.
PMID: 33364576
CD32 has raised conflicting results as a putative marker of the HIV-1 reservoir. We measured CD32 expression in tissues from viremic and virally suppressed humanized mice treated relatively early or...
12.
De Clercq J, Rutsaert S, De Scheerder M, Verhofstede C, Callens S, Vandekerckhove L
Acta Clin Belg
. 2020 May;
77(1):168-176.
PMID: 32468932
: In the last decade, there has been increasing scientific and legislative focus on antiretroviral treatment (ART) for all people living with HIV. Especially early ART initiation, preferably during acute...
13.
Pannus P, Rutsaert S, De Wit S, Allard S, Vanham G, Cole B, et al.
J Int AIDS Soc
. 2020 Feb;
23(2):e25453.
PMID: 32107887
Introduction: Viral remission after analytical treatment interruption (ATI), termed post-treatment control, has been described in a small proportion of HIV-positive patients. This phenomenon has been separately associated to both low...
14.
De Scheerder M, Van Hecke C, Zetterberg H, Fuchs D, De Langhe N, Rutsaert S, et al.
J Antimicrob Chemother
. 2020 Feb;
75(5):1311-1320.
PMID: 32053203
Background: Validated biomarkers to evaluate HIV-1 cure strategies are currently lacking, therefore requiring analytical treatment interruption (ATI) in study participants. Little is known about the safety of ATI and its...
15.
Lambrechts L, Cole B, Rutsaert S, Trypsteen W, Vandekerckhove L
Viruses
. 2020 Feb;
12(2).
PMID: 32012811
While current antiretroviral therapies are able to halt HIV-1 progression, they are not curative, as an interruption of treatment usually leads to viral rebound. The persistence of this stable HIV-1...
16.
De Scheerder M, Vrancken B, Dellicour S, Schlub T, Lee E, Shao W, et al.
Cell Host Microbe
. 2019 Sep;
26(3):347-358.e7.
PMID: 31471273
Viral rebound upon stopping combined antiretroviral therapy poses a major barrier toward an HIV cure. Cellular and anatomical sources responsible for reinitiating viral replication remain a subject of ardent debate,...
17.
Rutsaert S, De Spiegelaere W, De Clercq L, Vandekerckhove L
J Antimicrob Chemother
. 2019 Jul;
74(10):3030-3034.
PMID: 31314108
Background: The gold standard for HIV-1 treatment is to administer triple antiretroviral therapy, but a shift to simplified regimens is being explored. Boosted darunavir monotherapy can be considered for patients...
18.
Rutsaert S, Steens J, Gineste P, Cole B, Kint S, Barrett P, et al.
J Virus Erad
. 2019 Feb;
5(1):10-22.
PMID: 30800421
Objectives: To assess the safety and tolerability as well as antiretroviral impact of ABX464, an oral investigational drug with a novel mechanism of HIV-1 inhibition (ClinicalTrials.gov NCT02735863). Methods: Randomised, double-blind,...
19.
Van Hecke C, Trypsteen W, Malatinkova E, De Spiegelaere W, Vervisch K, Rutsaert S, et al.
EBioMedicine
. 2019 Feb;
41:443-454.
PMID: 30770230
No abstract available.
20.
Pannus P, Adams P, Willems E, Heyndrickx L, Florence E, Rutsaert S, et al.
AIDS
. 2019 Feb;
33(3):387-398.
PMID: 30702513
Objective: To determine whether viral suppressive capacity (VSC) of CD8+ T cells can be boosted by stimulation with HIV-1 peptides and whether the ability to control HIV-1 replication correlates with...